Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations (Q58481795)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

lymphoblastic leukemia

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Christine J Harrison

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Anthony V. Moorman

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

T D Buitenkamp

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

R Pieters

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

N E Gallimore

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A van der Veer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

H B Beverloo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

M Zimmermann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

V de Haas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

S M Richards

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A J Vora

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

C D Mitchell

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

L J Russell

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

C Schwab

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

M M van den Heuvel-Eibrink

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

M L den Boer

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

C M Zwaan

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

22 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

2204-2211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2012.84

26 January 2020

exact match

0 references

cites work

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Molecular insights into Down syndrome-associated leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

JAK mutations in high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Annotation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

7 January 2021

The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

7 January 2021

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

7 January 2021

Acute leukaemia in children with Down syndrome: a population-based Nordic study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

7 January 2021

Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.84

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22441210%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference